COVID-19 and Italy: what next?
Identifieur interne : 000B75 ( an2020/Analysis ); précédent : 000B74; suivant : 000B76COVID-19 and Italy: what next?
Auteurs : Andrea Remuzzi [Italie] ; Giuseppe RemuzziSource :
- Lancet (London, England) [ 1474-547X ] ; 2020.
Abstract
The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already taken on pandemic proportions, affecting over 100 countries in a matter of weeks. A global response to prepare health systems worldwide is imperative. Although containment measures in China have reduced new cases by more than 90%, this reduction is not the case elsewhere, and Italy has been particularly affected. There is now grave concern regarding the Italian national health system's capacity to effectively respond to the needs of patients who are infected and require intensive care for SARS-CoV-2 pneumonia. The percentage of patients in intensive care reported daily in Italy between March 1 and March 11, 2020, has consistently been between 9% and 11% of patients who are actively infected. The number of patients infected since Feb 21 in Italy closely follows an exponential trend. If this trend continues for 1 more week, there will be 30 000 infected patients. Intensive care units will then be at maximum capacity; up to 4000 hospital beds will be needed by mid-April, 2020. Our analysis might help political leaders and health authorities to allocate enough resources, including personnel, beds, and intensive care facilities, to manage the situation in the next few days and weeks. If the Italian outbreak follows a similar trend as in Hubei province, China, the number of newly infected patients could start to decrease within 3-4 days, departing from the exponential trend. However, this cannot currently be predicted because of differences between social distancing measures and the capacity to quickly build dedicated facilities in China.
DOI: 10.1016/S0140-6736(20)30627-9
PubMed: 32178769
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000438
- to stream PubMed, to step Curation: 000438
- to stream PubMed, to step Checkpoint: 000B09
- to stream Ncbi, to step Merge: 001157
- to stream Ncbi, to step Curation: 001157
- to stream Ncbi, to step Checkpoint: 001157
- to stream Main, to step Merge: 000B77
- to stream Main, to step Curation: 000B75
- to stream Main, to step Exploration: 000B75
- to stream an2020, to step Extraction: 000B75
Links to Exploration step
pubmed:32178769Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">COVID-19 and Italy: what next?</title><author><name sortKey="Remuzzi, Andrea" sort="Remuzzi, Andrea" uniqKey="Remuzzi A" first="Andrea" last="Remuzzi">Andrea Remuzzi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Management Information and Production Engineering, University of Bergamo, Dalmine, Italy. Electronic address: andrea.remuzzi@unibg.it.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Management Information and Production Engineering, University of Bergamo, Dalmine</wicri:regionArea><wicri:noRegion>Dalmine</wicri:noRegion></affiliation></author><author><name sortKey="Remuzzi, Giuseppe" sort="Remuzzi, Giuseppe" uniqKey="Remuzzi G" first="Giuseppe" last="Remuzzi">Giuseppe Remuzzi</name><affiliation><nlm:affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS.</nlm:affiliation><wicri:noCountry code="no comma">Istituto di Ricerche Farmacologiche Mario Negri IRCCS.</wicri:noCountry></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32178769</idno><idno type="pmid">32178769</idno><idno type="doi">10.1016/S0140-6736(20)30627-9</idno><idno type="wicri:Area/PubMed/Corpus">000438</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000438</idno><idno type="wicri:Area/PubMed/Curation">000438</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000438</idno><idno type="wicri:Area/PubMed/Checkpoint">000B09</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000B09</idno><idno type="wicri:Area/Ncbi/Merge">001157</idno><idno type="wicri:Area/Ncbi/Curation">001157</idno><idno type="wicri:Area/Ncbi/Checkpoint">001157</idno><idno type="wicri:Area/Main/Merge">000B77</idno><idno type="wicri:Area/Main/Curation">000B75</idno><idno type="wicri:Area/Main/Exploration">000B75</idno><idno type="wicri:Area/an2020/Extraction">000B75</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">COVID-19 and Italy: what next?</title><author><name sortKey="Remuzzi, Andrea" sort="Remuzzi, Andrea" uniqKey="Remuzzi A" first="Andrea" last="Remuzzi">Andrea Remuzzi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Management Information and Production Engineering, University of Bergamo, Dalmine, Italy. Electronic address: andrea.remuzzi@unibg.it.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Management Information and Production Engineering, University of Bergamo, Dalmine</wicri:regionArea><wicri:noRegion>Dalmine</wicri:noRegion></affiliation></author><author><name sortKey="Remuzzi, Giuseppe" sort="Remuzzi, Giuseppe" uniqKey="Remuzzi G" first="Giuseppe" last="Remuzzi">Giuseppe Remuzzi</name><affiliation><nlm:affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS.</nlm:affiliation><wicri:noCountry code="no comma">Istituto di Ricerche Farmacologiche Mario Negri IRCCS.</wicri:noCountry></affiliation></author></analytic><series><title level="j">Lancet (London, England)</title><idno type="eISSN">1474-547X</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already taken on pandemic proportions, affecting over 100 countries in a matter of weeks. A global response to prepare health systems worldwide is imperative. Although containment measures in China have reduced new cases by more than 90%, this reduction is not the case elsewhere, and Italy has been particularly affected. There is now grave concern regarding the Italian national health system's capacity to effectively respond to the needs of patients who are infected and require intensive care for SARS-CoV-2 pneumonia. The percentage of patients in intensive care reported daily in Italy between March 1 and March 11, 2020, has consistently been between 9% and 11% of patients who are actively infected. The number of patients infected since Feb 21 in Italy closely follows an exponential trend. If this trend continues for 1 more week, there will be 30 000 infected patients. Intensive care units will then be at maximum capacity; up to 4000 hospital beds will be needed by mid-April, 2020. Our analysis might help political leaders and health authorities to allocate enough resources, including personnel, beds, and intensive care facilities, to manage the situation in the next few days and weeks. If the Italian outbreak follows a similar trend as in Hubei province, China, the number of newly infected patients could start to decrease within 3-4 days, departing from the exponential trend. However, this cannot currently be predicted because of differences between social distancing measures and the capacity to quickly build dedicated facilities in China.</div></front></TEI><affiliations><list><country><li>Italie</li></country></list><tree><noCountry><name sortKey="Remuzzi, Giuseppe" sort="Remuzzi, Giuseppe" uniqKey="Remuzzi G" first="Giuseppe" last="Remuzzi">Giuseppe Remuzzi</name></noCountry><country name="Italie"><noRegion><name sortKey="Remuzzi, Andrea" sort="Remuzzi, Andrea" uniqKey="Remuzzi A" first="Andrea" last="Remuzzi">Andrea Remuzzi</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/an2020/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B75 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/an2020/Analysis/biblio.hfd -nk 000B75 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV2
|flux= an2020
|étape= Analysis
|type= RBID
|clé= pubmed:32178769
|texte= COVID-19 and Italy: what next?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/an2020/Analysis/RBID.i -Sk "pubmed:32178769" \
| HfdSelect -Kh $EXPLOR_AREA/Data/an2020/Analysis/biblio.hfd \
| NlmPubMed2Wicri -a CovidV2
| This area was generated with Dilib version V0.6.33. |  |